

SOHM, INC.
ANNUAL REPORT
FOR THE YEAR ENDED
DECEMBER 31, 2017

**ISSUER INFORMATION FILE PURSUANT TO SECURITIES AND EXCHANGE
COMMISSION RULE 15c2-11**

**SOHM, Inc.
(a Nevada corporation)**

December 31, 2017

TRADING SYMBOL: SHMN

CUSIP #: 83408P 108

TAX EIN NUMBER: 20-3161788

SHAREHOLDERS OF RECORD: 342

Information provided pursuant to Rule 15c2-11 of the Securities and Exchange Act of 1934, as amended.

The information furnished herein has been prepared from the books and records of the issuer by its officers and directors in accordance with the Securities and Exchange Commission Rule 15c2-11 as amended, and is intended only as a securities dealer informational file and: No dealer, salesman or any other person has been authorized to give any information, or to make any representations, not contained herein in connection with the issuer. Such information or representations, if made, must not be relied upon as having been authorized by the issuer, and: Delivery of this information file does not at any time imply that the information contained herein is correct as of any time subsequent to the date first written above.

Information required to conform with the provisions of subparagraph (a) (4) of Rule 15c2-11 promulgated by the Securities and Exchange Commission under the Securities Exchange Act of 1934.

1) Name of the issuer and its predecessors (if any)

SOHM, Inc. (the “Issuer” or the “Company”) formerly Alpine TLI Group, Inc.

The Issuer was organized under the corporate laws of the State of Nevada on July 6, 2005. The Issuer operated as a California C Corporation from January, 1998, until it merged with Alpine TLI Group in August, 2008 and changed its name to SOHM Inc.

2) Address of the issuer’s principle executive offices:

4195 Chino Hills Parkway, Suite 675
Chino Hills, CA 91709 USA
Telephone: (714) 522-6700
Facsimile: (714) 523-4329
Web site: www.sohm.com

Investor relations person's name:	N/A
Investor relations person's tele #:	714-522-6700
Investor relations person's email:	IR@SOHM.COM
Investor relations person's address:	SOHM Inc. 4195 Chino Hills Parkway, Suite 675 Chino Hills, CA 91709 USA

3) Security Information

A. Trading Symbol: SHMN
Class of Stock: Common Stock
CUSIP #: 83408P 108
As of 12/31/17:
Par Value: \$0.0001
Authorized shares of Common Stock: 1,000,000,000
Shares outstanding: 1,439,032,305

B. Trading Symbol: SHMN
Class of Stock: Preferred Stock
CUSIP #: N/A
As of 12/31/17:
Par Value: \$0.0001
Authorized shares of Preferred Stock: 100
Shares outstanding: 51

Transfer Agent

Pacific Stock Transfer Company
6725 Via Austi Pkwy, Suite 300
Las Vegas, Nevada 89119
Phone-702.361.3033
Fax- 702.433.1979
Toll Free – 800.785.PSTC(7782)

Pacific Stock Transfer Company is registered with the Securities and Exchange Commission, which is the appropriate regulatory authority of the transfer agent.

List any restrictions on the transfer of security:

None.

Describe any trading suspension orders issued by the SEC in the last 12 months.

None.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off or reorganization either currently anticipated or that occurred within the last 12 months:

None.

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

On July 1, 2016, Shailesh Shah retired his 107,604,173 common shares and on July 13, 2016, Shailesh Shah transferred all of his shares of Series A Preferred stock (51 shares).

5) Financial Statements

Please see financial statements at the end of this disclosure.

6) Describe the Issuer's Business, Products and Services.**A. Generic Pharmaceutical Manufacturer****Company Overview**

SOHM, Inc. (SHMN) is a pharmaceutical manufacturer that produces and markets generic drugs for all major treatment categories. In February, 2009, the Company obtained a direct manufacturing license under Current Good Manufacturing Practice (CGMP) and initiated processes to be compliant with World Health Organization (WHO) regulations to produce generic as well as OTC pharmaceuticals. This authorization process provides the Company with manufacturing competencies for a wide variety of products covering various therapeutic segments. SHMN has private label license agreements with two companies to produce pharmaceuticals and OTC products.

The Company's manufacturing facility, located in India, enables low production costs without compromising quality. SHMN develops, manufactures and markets generic pharmaceuticals in various dosage forms, including tablets and capsules, creams and topicals, ointments, liquids and injectables. At present, SHMN has global licenses to manufacture 30 products and approximately 300 generic drugs and product formulations for distribution.

SHMN markets and sells its generic drugs globally but focuses primarily on emerging markets in Africa, Latin America, Southeast Asia and the European Union. The Company's global headquarters is located in North America and it has offices in China, India and the U.K.

Generic Drug Manufacturing Expertise

SHMN's proprietary processes and formulation capability allow it to develop generic formulations of brand name drugs that don't infringe on valid patents relating to the brand-name product. Demand for generic pharmaceuticals is increasing as a result of increasing awareness and acceptance of generics by consumers, physicians and pharmacists globally. In addition, government agencies and private managed care/ insurance programs encourage the substitution of generics for brand-name pharmaceuticals as a cost savings measure. SHMN has developed ability to bridge the gap between demand and supply for generic and OTC products cost effectively with consistent quality deliverables.

Infrastructure To Support Manufacturing and Export

By consolidating its pharmaceutical assets in India, the Company has a generic drug manufacturing hub where it capitalizes on low prices, strong marketing and global recognition of India's emerging role as a leading drug manufacturing center. In October 2008, SHMN obtained pharmaceutical drug licenses that enable it to sell in Africa, Latin America and Southeast Asia. In February 2009, SHMN obtained a direct manufacturing license for generic pharmaceuticals. This license completes the needed infrastructure development for its India manufacturing hub.

1. Issuer is a Nevada Corporation;
2. The Issuer operated as a California C Corporation from January, 1998, until it merged with Alpine TLI Group in August, 2008. The Issuer's predecessor was organized under the corporate laws of the State of Nevada on July 6, 2005.
3. The Issuer's fiscal year end date is December 31.
4. The issuer and/or any predecessor has not, and is not, in the process of filing bankruptcy, receivership or any similar proceeding.
5. On August 25, 2008, SHMN entered into an agreement with Alpine TLI Group, Inc., the predecessor. The agreement was to acquire SHMN and pass control of the Company to the then current officers of SHMN being Swati Shah, President/CEO and Sharad Joshi, Secretary/Treasurer and CFO.
6. No default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the Issuer to make payments as of the most recent quarter and year end.
7. The Issuer changed control when it merged in September 2008.
8. The increases in outstanding equity securities have increased by more than 10%.
9. Below is a description of any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization

On August 26, 2008, the Board of Directors and majority shareholders of Alpine TLI Group, Inc. voted and confirmed the following:

▪ **Corporate Name Change, CUSIP Number Change and New Business Direction**

The stockholders and Board Members of Alpine TLI, Group voted to confirm the change of the name of the corporation to SOHM, Inc and also to apply for a new CUSIP number. The name change and CUSIP number change reflects the company's new business direction to directly supply dyes, chemicals, pigments, and supply steel wires to manufacturers for springs, automobiles and garment/textile industries through private label agreements.

▪ **Merger with SOHM Inc.**

The stockholders and Board Members voted to confirm the merger with SOHM, Inc.

▪ **Reverse Split**

The stockholders and Board Members voted to confirm a 50:1 reverse split.

▪ **CEO and Chairman Change**

The stockholders and board members voted to confirm a CEO and Chairman change effective September 5, 2008. Then current CEO and Chairman resigned and Ms. Swati Shah assumed the position of President, CEO and Chairman of the Board and Mr. Sharad Joshi assumed the position of Secretary, Treasurer, CFO and Board Member. Mr. Sharad Joshi resigned as Secretary, Treasurer, CFO and Director effective March 31, 2009. Effective January 15, 2011 the stockholders & Board members voted to confirm a CEO & Chairman change. The then current CEO & Chairman Ms. Swati Shah resigned as President & CEO and took over as Vice President, Secretary & Director. Mr. Shailesh Shah assumed the position of President, CEO & Chairman of the Board. On August 31, 2015, Mr. Shailesh Shah resigned as President, CEO and Director. Swati Shah was appointed as President, CEO and Director and retained her appointment as Secretary, Treasurer and CFO.

10. Issuer's securities have not been de-listed and are not in the process of being de-listed by the Securities and Exchange Commission or the NASD.

11. There are no current, past, pending or threatened legal proceedings or administrative actions either by or against the issuer that could have a material effect on the issuer's business, financial condition, or operations.

B. Business of Issuer

1. The Primary SIC Code for the Issuer is 2834.
2. The Issuer is currently conducting operations.
3. The issuer is not and has not been a shell company.
4. There is no parent, or affiliate of the issuer.
5. The effect of the existing and probable new government regulations is that issuer is alert and watchful so as to be able to re-evaluate portions of its business plan.
6. No amount has been spent during each of the last two fiscal years on research and development activities, therefore no cost of such activities are borne directly by customers.

7. There are no known costs or effects of compliance with environmental laws, neither International, federal, state or local.
8. The Company currently has one hundred forty-five, (145) full time employees.

C. Investment Policies

1. Investments in real estate or interest in real estate

The Issuer does not intend to invest in Real Estate outside of ownership in its executive offices or manufacturing facilities

2. Investments in real estate mortgages

The Issuer does not intend to invest in any type of real estate mortgages.

3. Investments in Securities

The Issuer does not intend to invest in short term or long term securities

D. The nature of products and services offered

Services Provided by SHMN, and their Markets

SHMN develops and commercializes generic pharmaceuticals, utilizing its controlled-release and other in-house and formulation technologies. The Company focuses on developing generic versions of brand-name products for which the patents are near expiration or expired and requiring a proprietary formulation expertise. By innovating processes, and applied innovation, the Company's proprietary processes and formulation skills allow it to develop generic versions that replicate the brand-name products' physiological effects but don't infringe on any valid patents.

The Company actively reviews pharmaceutical patents and seeks opportunities to challenge patents it believes are either invalid or would not be infringed by a generic version. SHMN also enters into collaboration, alliances and partnerships to acquire rights to pharmaceuticals it does not own and to share development costs or resolve patent barriers to entry. Overall, the Company's generic product development strategy leverages a legal strategy predicated on non-infringement of established brand name pharmaceuticals and speed of filing and also provide applied innovation.

The Company has a direct manufacturing license of generic pharmaceuticals and currently produces and markets 300 plus generic pharmaceutical products along with dermatology and Nutraceutical products. The classification and industry position allows for a significant increase in profit margins and scalability of manufacturing operations. This license provides SHMN the production infrastructure to operate as a corporate manufacturing hub located in India for the production and export of generic pharmaceuticals.

CORPORATE OVERVIEW

The Company's manufacturing facility is located in Ahmedabad City, India, in an area considered one of the safest in India and perfect for pharmaceutical operations. The facility is approximately 10,500 square feet and the entire land area is approximately 15,000 square feet. There is additional space available for future capacity expansions and growth and storage requirements. In February 2009, SHMN's manufacturing facility was licensed by the India FDA. The license indicates compliance with Current Good Manufacturing Practice (CGMP) Regulations: Division of Manufacturing and Product Quality and compliant with World Health Organization (WHO) regulations.

The manufacturing facility provides complete technical support for production activities and houses the following:

- A quality control laboratory with instruments to provide, chemical and microbiological analytical support; to provide constant in process checks
- A spacious raw materials storage area which provides separate storage facilities for incoming materials, quarantine materials, released materials and a separate section for sampling under controlled environment and isolated areas for dispensing of raw materials; through documented SOPs for stringent control systems of checks and balances.
- A finished goods warehouse for storage and distribution of finished goods.

Corporate Strategy

The Company produces premium-quality, affordable pharmaceuticals and meets the changing needs of the drug market with a continual flow of new products, broadening its product portfolio, optimizing a global supply chain, helping customers more efficiently manage their inventory and customizing distribution and shipping based on specific customer needs. SHMN plans to grow by extending its leadership position in emerging generic pharmaceutical markets in Africa, Latin America, Southeast Asia and other important international markets.

Key aspects of the Company's strategy include:

- Undertake applied innovation to find optimum fit between demand and supply gaps in generic industry.
- Increasing generic R&D capabilities, and applied formulations with continuous incremental improvement which adds up to sustained innovative output, and greater production capacity;
- Establishing a high level of operational effectiveness oversight and quality control systems;
- Bridge the gap between demand and supply in cost effective generics and branded generics; Providing high-quality products in markets that are currently under served, poorly served, or under-subscribed by existing suppliers;
- Using cost-effective, up-to-date instruments and equipment and machineries; on an ongoing basis.
- Employing advanced electronic and information technology to reduce staffing and other operational costs; providing more system based output with minimal human errors,
- Continuing to business scanning actively seek and evaluate potential mergers, acquisitions, collaborations and other business combinations; to enlarge capacities, competencies and innovations;
- Side stepping head-to-head competition with an established business in regions that already are well served and develop alternatives for unmet needs to enlarge innovative generics portfolio.

Sales and Marketing

The Company's focus on cluster of segment of customers who are drug wholesalers, mass merchandisers, warehousing chain drug stores, and mail-order pharmacies who have extensive chain of retailers and loyal customer base, by doing so, SHMN does not need to re-invent its grass root customers but rather SOHM markets its products both directly and through partner alliance agreements. SHMN focuses on fast

growing, underserved emerging markets in the Far East, Africa, newly added European Union states and Latin America. Despite the challenges of the current economic climate, much of the world's population has a great need for basic pharmaceuticals, but these drugs are either too expensive or not available to vast populations in these regions. The Company recently expanded its generic drug distribution to address emerging pharmaceutical markets in Indonesia, Thailand, the Philippines, and Malaysia.

The Company's marketing effort focuses on:

- Identifying, through careful market research, un-served or underserved niche markets;
- Combining the core pharmaceutical business with ancillary marketing concepts, activities and operations;
- Identifying, negotiating, and entering into partnerships with larger, more established distributors;
- Utilizing advanced electronic and informational technologies in sales and marketing;
- Accommodating special and ethical products when and where sufficient demand exists.

Products

SHMN produces and markets generic drugs covering all major treatment categories. Its product list includes anti-arthritic/analgesics, anticancer drugs, antifungals, anti-infectives, cardiovascular agents, central nervous system, dermatological, gastrointestinal and respiratory drugs, biotechnology products, hormones, anesthetics, antidiabetics, antiemetics, dermatologicals, immunosuppressive agents, ophthalmic drugs, and treatments for benign prostatic hyperplasia

SHMN's manufacturing facility is licensed by the India FDA to manufacture:

- **TABLETS:** uncoated; coated; chewable; dispersible;
- **CAPSULES** - hard gelatin capsules; dry syrup;
- **ORAL LIQUIDS** - syrups and suspensions;
- **OINTMENT** - external creams & gels;
- **β - LACTUM:** tablets; capsules; dry syrup;
- **INJECTABLES.**

E Sources of raw materials for the Company's generic drugs are freely available.

F The non-dependence on one or a few major customers is a strength.

G The Company maintains trademarks for all of its private label products.

H In February 2009, SHMN's manufacturing facility was licensed by the India FDA. The license indicates compliance with Current Good Manufacturing Practice (CGMP) Regulations: Division of Manufacturing and Product Quality and World Health Organization (WHO) regulations.

7) Describe the Issuer's Facilities

The Issuer occupies approximately 1500 square feet of office space that is being leased by a company that is owned by the company's prior officer and director. The Issuer does not pay any rent for this space. The Issuer believes that the space is in good condition and properly insured. The major assets of the company comprise the following:

The Company is headquartered in Chino Hills, California, U.S.A. and the Company's manufacturing facility is located in Ahmedabad City, India, in an area considered one of the safest in India and perfect for pharmaceutical operations. The facility is approximately 10,500 square feet and the entire land area is approximately 15,000 square feet.

Property of the issuer is in good condition. There are no limitations on the expansion capability of the Company.

8) Officers, Directors and Control Persons

A. Officers and Directors

Swati Shah – Sole Officer and Director, Control Person
Bhat Family Trust - Control Person

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses); - No.

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities; - No.

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or; - No.

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities – No.

C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

None.

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel

W. Scott Lawler, Esq.
Booth Udall Fuller, PLC
1255 W. Rio Salado Parkway, Suite 215
Tempe, AZ 85281
(480) 830-2700
wsl@boothudall.com

Accountant or Auditor

Umesh Savani Tax Services
Nutwood Avenue
Placentia, CA 92870

10) ISSUER CERTIFICATION

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

I, Baron Night certify that:

1. I have reviewed this 2017 annual disclosure statement of SOHM, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated this 19TH day of December, 2018.

SOHM, INC.

/s/ Baron Night
Baron Night, CEO & CFO

SOHM, INC.
FINANCIAL STATEMENT
FOR THE YEARS ENDED
DECEMBER 31, 2017 and 2016

SOHM, INC. FINANCIAL REPORT FOR THE YEARS ENDED DECEMBER 31, 2017 and 2016

Item 1: Exact name of the issuer and the address of its principal executive offices.

Name of the Issuer: SOHM, Inc.

Principal Executive Offices: 4195 Chino Hills Parkway, #675,
Chino Hills, CA 91709 USA

Telephone: (714) 522-6700
Facsimile: (714) 523-4329
Web site: www.sohm.com

Investor Relations Officer: N/A

Investor Relations Office: SOHM, Inc.
4195 Chino Hills Parkway, #675,
Chino Hills, CA 91709 USA

Investor Relations Telephone: 714-522-6700
Investor Relations Fax: 714-523-4329
Investor Relations Email: IR@sohm.com

Item 2 Shares outstanding.

The following table sets forth information concerning the equity securities of SOHM, Inc. as of December 31, 2017:

SECURITIES AUTHORIZED AND OUTSTANDING Class	As of	Number of Shares Authorized	Number of Shares Outstanding	Total Number of Shareholders of Record
Common	December 31, 2017	1,000,000,000	1,439,032,305	341
Preferred	December 31, 2017	100	51	1

SOHM, INC.
QUARTERLY REPORT
FOR THE QUARTER ENDED December 31, 2017
BALANCE SHEET
As of December 31, 2017
(Unaudited)

ASSETS			USA all Qtr	As of December 31, 2017	As of Dec 31 2016
CURRENT ASSETS					
Cash			2,180	2,180	479
Trade Receivables			8,424	8,424	7,768
Loans and Advances			-	-	-
Inventory			25,500	25,500	25,500
Total Current Assets			36,104	36,104	33,747
EQUIPMENT, net			-	-	-
OTHER ASSETS					
Subscribed Shares Note		-	120,170	120,170	215,257
Prepaid Expenses		-	-	-	-
Reserves and Surplus					
Total Other Assets			-	120,170	215,257
TOTAL ASSETS			156,274	156,274	249,004

SOHM, INC.
FOR THE YEAR ENDED December 31, 2017
BALANCE SHEET
As of December 31, 2017
(Unaudited)

LIABILITIES AND STOCKHOLDERS' EQUITY			USA all Qtr	As of December 31, 2017	As of Dec 31 2016
CURRENT LIABILITIES					
Payables			120,230	120,230	129,027
Loan Payable and other current liabilities			-	-	-
Accrued Tax & Payroll liabilities			61,580	61,580	51,580
Total Current Liabilities			181,810	181,810	180,607
LONG TERM NOTES PAYABLE			1,212,510	1,212,510	1,228,783
LOAN PAYABLE TO BANK & OTHERS			60,532	60,532	74,051
Total Liabilities			1,454,852	1,454,852	1,483,441
STOCKHOLDERS' EQUITY					
Common Stock, authorized 1,000,000,000 shares of stock, and 1,439,032,305 issued and outstanding at December 31, 2017 par value \$0.001 per share and Preferred Stock authorized 100 share of stock and 51 issued and outstanding at December 31, 2017 par value \$0.001 per share				3,798,426	3,798,426
Additional Paid in Capital				-	-
Subscribed Shares			445,504	445,504	445,504
Retained Earnings (Loss)			(1,744,082)	(1,744,082)	(1,679,941)
Total Stockholders' Equity			156,274	156,274	249,004
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY				156,274	249,004

SOHM, INC. STATEMENT OF OPERATIONS / Income Statement For the Year Ended December 31, 2017 (Unaudited)					
Particulars			All Qtr	Dec.31,2017	As of Dec 31 2016
INCOME					
Revenue			173955	173,955	124,261
Total Revenue			173955	173,955	124,261
COST OF SALES					
Cost of Goods Sold			70,589	70,589	30,255
Total Cost of Sales			70,589	70,589	30,255
Gross Profit			103,366	103,366	94,006
EXPENSES					
Sales and Marketing			6,331	6,331	25
General and Administrative			160,906	160,906	114,138
Research and Development			-	-	-
Depreciation Expense				-	-
Interest Expense			270	270	1,660
Total Expense			167507	167,507	115,823
Net Income before extraordinary Items			(64,141)	(64,141)	(21,817)
Extraordinary Items		-	-	-	-
Loss before Provision for		-	-	-	-
Income Taxes		-	-	-	-
Provision for Income Taxes		-	-	-	-
NET INCOME (LOSS)		-	(64,141)	(64,141)	(21,817)
Basic and Diluted Earnings					
Earnings (Loss) per Common Share		0	0	-	0
Basic and Diluted Weighted Average					
Number of Common Shares				1,439,032,305	1,439,032,305

SOHM, INC. STATEMENT OF CASH FLOWS as of December 31,2017 (Unaudited)						
Particulars					Total As of December 31, 2017	As of Dec 31 2016
Cash Flows from						
Operating Activities						
Net Income (Loss)					(64,141)	(21,817)
Adjustment to Retained Earnings					-	-
Accounts Receivable					(656)	491,489
Inventory					-	297,847
Loans and Advances					-	53,038
Accounts Payable					(8,797)	(1,259,447)
Loans Payable					(29,792)	(1,047,330)
Accrued Payroll liabilities					10,000	(124,120)
Current Liabilities-others					-	-
Depreciation Expense					-	-
Amortization Expense					-	-
Stock Issued for services					-	-
Stock Issued for special interest					-	-
Stock issued for capital						
Net Cash Provided by Operations					(93,386)	(1,610,340)
Cash Flows Used in Investing Activities						
Fixed Asset Purchase (Sale)					-	1,174,161
Other Assets					95,087	434,435
Net Cash Used for Investing					95,087	1,608,596
Cash Flows from Financing						
Notes Payable					-	
Sales of Stock					-	
Capital Contributions					-	-
Subscribed Shares Note						
Special Interest					-	-
Cash Flows from Financing					-	-
Net Increase (Decrease) in Cash					1,701	(1,744)
Cash, Beginning of Period					479	2,223
Cash, End of Period					2,180	479

SOHM, INC.
STATEMENT OF STOCKHOLDERS' EQUITY
As of December 31, 2017
(Unaudited)

	Common Stock		Additional Paid in Capital	Stock Subscribed	Accumulated Deficit	Total Equity
	Shares	Amount				
Balance, December 31, 2004	-	-	4,200		(8,125)	(3,925)
Sales of Common Stock	260,000	260	12,740			13,000
Common Stock Issued for						
Conversion of LLC Interest	4,000,000	4,000	(4,200)			(200)
Common Stock Issued for						
Services Rendered	14,000,000	14,000	-			14,000
Deficit for year to date					(308,429)	(308,429)
Balance, December 31, 2005	18,260,000	18,260	12,740	0	(316,554)	(285,554)
Common Stock Issued for						
Special Interest	550,000	550	7,700			8,250
Common Stock Issued for						
Services Rendered	85,500,000	85,500	1,197,000			1,282,500
Common Stock Issued for						
Subscriber Shares Note	10,000,000			150,000		150,000
Deficit for year to date					(1,456,410)	(1,456,410)
Balance, December 31, 2006	114,310,000	104,310	1,217,440	150,000	(1,772,964)	(301,214)
Balance September 30, 2010	283,168,626	1,750,590	0	0	(1,896,462)	(145,872)
Balance December 31, 2010	329,107,088	2,059,946	0	0	(2,083,579)	(23,633)
Balance March 31, 2011	333,107,088	2,059,946	0	0	(2,244,598)	(184,652)
Balance June 20, 2011	368,323,806	2,359,946	0	0	(2,522,128)	(164,182)
Balance Sept 30, 2011	431,828,755	3,074,946	0	0	(2,580,349)	494,597
Balance December 31, 2011,	432,278,806	3,074,946	0	0	(2,632,569)	442,377
Balance December 31, 2012	496,063,353	3,249,196	0	0	(3,953,145)	(703,949)
Balance December 31, 2013	496,063,404	3,249,196	0	0	(4,977,426)	(703,949)
Balance March 31, 2014	534,230,020	534,230	0	0	(5,009,898)	(1,226,472)
Balance June 30, 2014	549,230,020	15,000	0	0		
Balance September 30, 2014	559,922,379					
Balance December 31, 2014	559,922,379					
Balance March 31, 2015	691,057,826					
Balance June 30, 2015	1,098,646,738	37,500	0	0		
Balance September 30, 2015	1,317,155,868	25,000	0	0		
Balance December 31, 2015	1,546,636,529	0	0	0		
Balance December 31, 2016	1,439,032,305	0	0	0		
Balance December 31, 2017	1,439,032,305	0	0	0		

SOHM, INC.

NOTES TO FINANCIAL STATEMENTS December 31, 2016 and December 31, 2017

NOTE 1.OVERVIEW OF OPERATIONS AND ACCOUNTING POLICIES:

SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia.

The Company's operations to date have included assembling its management, marketing and sales personnel, and forming strategic relationships with vendors, securing financing and launching the initial purchases of tax lien certificates.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As reflected in the accompanying financial statements, the Company had negative cash flow from operations and incurred a net loss during the previous twenty-two months. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to achieve sufficient cash flow from operations or secure adequate future financing and be therefore unable to continue as a going concern.

In the opinion of management, the accompanying balance sheets and related statements of income, cash flows, and stockholders' equity include all adjustments necessary for their fair presentation in conformity with U.S. generally accepted accounting principles. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results may differ from these estimates. The information included in this Form 211-75c should be read in conjunction with Management's Discussion and Analysis and financial statements and notes thereto included. Certain reclassifications have been made for consistent presentation.

Revenue Recognition

The Company generally recognizes revenue upon the accrual of interest earned on the tax lien certificates owned, as well as liquidating revenue from properties sold that the Company received through settlement of unredeemed tax lien certificates.

Deferred Revenue

The deferred revenue shown in the balance sheet is the interest earned but not collected.

Advertising, Sales & Marketing

Advertising, sales & marketing costs are expensed as incurred. Advertising, sales & marketing expense totaled \$25 for the year-ended December 31, 2016 and for the year ended December 31, 2017 totaled \$6,331.

Inventory

Inventory is stated at the lower of cost or net realizable value. The method used for inventory is first-in first out. Inventory consists of Pharmaceutical products
Property, Equipment and Patents.

Equipment is depreciated using the federal tax method over the estimated useful lives, which range from two to seven years.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Earnings per Share

The basic earnings (loss) per share is calculated by dividing the Company's net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company's net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.

The Company has no potentially dilutive securities outstanding at the end of the statement periods. Therefore, the basic and diluted earnings (loss) per share are presented on the face of the statement of operations as the same number.

Stock Based Compensation

The Company accounts for its stock based compensation based upon provisions in SFAS No. 123, Accounting for Stock-Based Compensation. In this statement stock based compensation is divided into two general categories, based upon who the stock receiver is, namely, employees/directors and non-employees/directors. The employees/directors category is further divided based upon the particular stock issuance plan, namely compensatory and non-compensatory. Each of these divisions treats the stock issuance for accounting purposes in a specific manner. The employee/directors non-compensatory securities are recorded when the stock is sold at the sales price. The compensatory stock may be recorded in one of two different methods. Compensation is calculated and recorded either at the securities' fair value or intrinsic value. The Company has selected to utilize the fair value method for valuing and recording options.

NOTE 2. NOTES PAYABLE AND CAPITAL LEASE OBLIGATIONS:

Notes payable and capital lease obligations consist of the following:

There are long term notes payable and the long –term portion.

	For Year Ended	
	12/31/2016	12/31/17
Total Long Term Notes	1,228,783	1,212,510
Total Loan Payable to Bank & Others	74,051	61,580

NOTE 3. STOCKHOLDERS' EQUITY:

Authorized Capital Stock

The Company has total authorized capital of 1,000,000,100 shares consisting of 1,000,000,000 shares of common stock, \$.001 par value per share and 100 Preferred Stock as of the date of the financial

statements. Of the 1,000,000,000 shares authorized 1,439,032,305 shares were issued and outstanding as of December 31, 2017.

Stock Based Compensation Paid for Services of Non Employees

SFAS 123 provides that stock compensation paid to non-employees be recorded with a value which is based upon the fair value of the services rendered or the stock given, whichever is more reliable. The common stock paid to non-employees was valued at the value of the stock issued. Below is a schedule which shows the common stock issued and the value of the services rendered.

Period Ended	Shares Issued	Value
December 31, 2017	0	\$0

NOTE 4 INCOME TAXES:

The Company provides for income taxes under Statement of Financial Accounting Standards No. 109, *Accounting for Income Taxes*. SFAS No. 109 requires the use of an asset and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse.

SFAS No. 109 requires the reduction of deferred tax assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. In the Company's opinion, it is uncertain whether they will generate sufficient taxable income in the future to fully utilize the net deferred tax asset. Accordingly, a valuation allowance equal to the deferred tax asset has been recorded. The total deferred tax asset is \$388,853, which is calculated by multiplying the minimum federal corporate income tax rates by the respective NOL carry forwards, (15%). The total valuation allowance is a comparable \$388,853.

The provision for income taxes is comprised of the net change in deferred taxes less the valuation account plus the current taxes payable as shown in the chart below.

	09/30/2017	12/31/16
Net change in deferred taxes plus valuation	0	0
Current taxes payable	<u>0</u>	<u>0</u>
Provision for Income Taxes	<u>0</u>	<u>0</u>

Below is a chart showing the federal net operating losses and the years in which they will expire.

Year	Amount	Expiration
2004	0	2024
2005	136,737	2025
2006	173,910	2026
2007	185,000	2027
2008	-	-
2009	567,232	2029
2010	980,457	2030
2011	548,990	2031
2012	1,131,326	2032
Total NOL	3,723,652	

NOTE 5. LEASES AND OTHER COMMITMENTS:

The following is a listing of the operating leases that the Company had as of the period end and the monthly charges associated with those leases. The office lease is a renewable lease with option to renew for the next two years starting on and ending each year on, for which a new option agreement to be signed 90 days in advance of expiration date, with a 5% increase or decrease based upon the fair market value determined by the increase or decrease in the prime rate. The office equipment is a fixed cost lease with staggered expiration dates two years from the date of agreement. The lease terms provide for a one dollar buyout option at the end of the lease for which management intends on exercising, such as making the lease a capital lease. The Capital lease is depreciated over the useful life of years

	12/31/2016	12/31/17
Office Equipment	4032.70	4032.70
Total Monthly	4032.70	4032.70

The monthly operating leases as of 12/31/16 projected into the future for five years shows the following commitments:

	Year 1	Year 2	Year 3	Year 4	Year 5
Total Yearly Leases	4032.70	4032.70	4032.70	4032.70	4032.70
Total Yearly Leases	4032.70	4032.70	4032.70	4032.70	4032.70

NOTE 6: GOING CONCERN:

Listed below are some of the challenges which the Company is facing, and why these raise a question as to the Company's ability to continue as a going concern. Afterward, the explanation of the going concern problems, management's plans to turn the Company around are described.

Company's Challenges--

The Company has survived only by raising funds. The Company must continue to raise funds in the near future to survive. Management has been successful in the past in raising these funds. There is no assurance that management can continue to find investors to cover the losses generated.

The need to provide working capital adequacy, is major challenge. For sustainable expansions of manufacturing competencies, increased stringency of regulatory framework and need for expanded management bandwidth to capture opportunities through innovation. The capacities and soft skill reinforce each other in face of outstanding opportunities. One of the major hurdle that is faced today is when large scale chain of store evaluates the products and innovation, it demand scale of response. The capacity build up requires sustained adequacy on funds as well as focus and visions of business enterprise.

NOTE 7. THE EFFECT OF RECENTLY ISSUED ACCOUNTING STANDARDS:

Below is a listing of the most recent accounting standards SFAS 142-144 and their effect on the Company.

SFAS 146 Accounting for Costs Associated with Exit or Disposal Activities

This statement requires companies to recognize costs associated with exit or disposal activities, other than SFAS 143 costs, when they are incurred rather than at the date of a commitment to an exit or disposal plan. Examples of these costs are lease termination costs, employee severance costs associated with

restructuring, discontinued operation, plant closing, or other exit or disposal activity. This statement is effective after December 15, 2002.

SFAS 147 Acquisitions of Certain Financial Institutions – an amendment of FASB Statement No. 72 and 144 and FASB Interpretation No. 9

This statement makes the acquisition of financial institutions come under the statements 141 and 142 instead of statement 72, 144 and FASB Interpretation No. 9. This statement is applicable for acquisition on or after October 1, 2002.

SFAS 148 Accounting for Stock-Based Compensation

This Statement amends FASB Statement No. 123, Accounting for Stock-Based Compensation, to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, this Statement amends the disclosure requirements of Statement 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results.

The adoption of these new Statements is not expected to have a material effect on the Company's financial position, results or operations, or cash flows.

NOTE 8. SEGMENT INFORMATION:

Segment information is presented in accordance with SFAS 131, Disclosures about Segments of an Enterprise and Related Information. This standard is based on a management approach, which requires segmentation based upon the Company's internal organization and disclosure of revenue based upon internal accounting methods. Currently management divides revenue into two categories, earnings relative to tax lien certificates and real estate owned.